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Abstract
Background: Breast cancer (BC) remains principally a disease of old ages; with 35-50% of cases occurring in
women older than 65 years. Even mortality for cancer increases with aging: 19.7% between 65 and 74 years; 22.6%
between 75 and 84 years; and 15.1% in 85 years or more.
The study was aimed to investigate specific predictive factors for elderly patients so to select the best way to treat
and follow these patients.
Methods: A search was performed on Medline, Embase, Scopus using the following Key words: Breast cancer,
Breast neoplasms, Aged, Elder, Elderly, Eldest, Older, Survival analysis, Prognosis, Prognostic factors, Tumor markers,
Biomarkers, Comorbidity, Geriatric assessment, Axilla, Axillary surgery. 3029 studies have been retrieved. Paper in
which overall or disease free survival were not end points, or age class was not well defined, or the sample was
too small, were excluded. At last 42 papers fulfilled the criteria.
Results and discussion: Lack of screening and delay in diagnosis may be responsible for the minor improvement
in survival observed in elderly respect to younger breast cancer patients. Predictive factors are the same and must
be assessed with the same attention reserved to younger women.
Conclusions: Most of elderly patient are fit to undergo standard treatment and can get the same benefits of
younger women. Nevertheless it is possible that some older women with early breast cancer can be spared too
aggressive treatments. Geriatric assessment and co-morbidities can affect the prognosis modifying surveillance, life
expectancy and compliance to therapies. They can thus be useful to select the better treatment, either surgical or
radio or hormone - or chemo-therapy.
Background
Breast cancer (BC) remains principally a disease of old
ages; with 35-50% of cases occurring in women older
than 65 years.
In the period 2004-2008, the National Cancer Insti-
tute’s Surveillance Epidemiology and End Results (SEER)
has reported that about 40% of BSs have been diagnosed
in elderly women: 19.7% in women aged between 65 and
74 years; 15,5% in women between 75 and 84 years, and
5.65% in those aged 85 years and older. Thus, mortality
for cancer increases with aging: 19.7% between 65 and
74 years; 22.6% between 75 and 84 years; and 15.1% in
85 years or more [1].
Similar results have also been reported by other
researchers (Table 1) [2-4].
The improvement in the 5-year survival observed in
the last decades in many countries (USA, GB, Italy, etc.)
in all classes of ages (Figures 1, 2) [1-4] is less evident
for older women [5]. Mortality for BC in USA has
decreased by 24% between 1990 and 2000, mostly in
younger women (3.3% per year), but less for older
women (2% per year) [1].
In a Third World series, survival is even lower, related
to the low life expectancy in these populations [6].
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Are these results related just to a lack in screening,
delayed diagnosis or to an under treatment?
In some study [7] the income influenced the probability
for over- 65 to undergo screening regularly and therefore
the prognosis, while a more recent study [8] on 173
women aged 80 years and older has showed a large per-
centage of early stages diagnoses: stage I (35%) and II
(32.9%), with about 50% of cases showing negative axillary
nodes. Less favorable are the data from Botteri [9] who
has observed that the incidence of positivity lowered with
the growing of age until 65 years, but increased thereafter.
Thus, a recent study in post-menopausal women with
Hormone Receptor positive breast cancer, reports a higher
disease specific mortality with increasing age [10]. Other
researchers have found a more frequent delay in diagnosis
in older women [11], even if the influence of such delay
cannot be definitely assessed [12].
To complicate the issue, most trials exclude women
older than 70 years and, on the other side, is quite diffi-
cult to recruit these women in randomized trials, as
demonstrated by the failure of a recent attempt [13].
Further, in some studies, the median follow up is just
about two years and the recorded mortality is often not
related to cancer (i.e., in the series of Solej, 8 out of 34
elderly patients died within two years, but only two deaths
were cancer-related) [14], making impossible to distinguish
the respective influence of the different prognostic factors.
While age is usually included among prognostic factors
for BC, which prognostic factors should we consider in
older women? Have such factors different value in older
women respect to younger? Answering to such questions
is the aim of the present paper.
Methods
Identification of key words. Three series of key words
(Table 2) were identified relating to the pathology
(Breast cancer), to the age of patients and to prognostic
factors.
Selection of studies
Reports investigating the role of prognostic factors in
elderly patient with non metastatic breast cancer were
selected for review using a search of PubMed, Embase,
Scopus from 2006 to date April 30, 2012, using the lists
of key words above indicated combined and crossed.
The search was limited to clinical trials, practice
guidelines and review available in the English language.
3029 citations were retrieved. Papers without available
abstract were excluded, Phase I, II, III pharmacological
studies, were excluded and so were male breast cancer
studies, case report or small series reports as well as
psychological and behavioral studies. The remaining
2128 titles have been checked one by one leading to
identify 243 possibly relevant papers.
The abstract or full text of all studies on breast cancer
prognostic or predictive factors, risk of recurrence and
survival have been reviewed to identify any relevant arti-
cle. Eligible reports were those that examined either
overall survival (OS) and/or disease free survival (DFS)
in clinical series of primitive invasive breast cancer
including over 70 years age patients; guidelines and
review have been selected for relevant information and
opinion. Articles where either OS or DFS were not used
as clinical endpoints or where the correlation between
prognostic factors and age was not evaluable were to be
Table 1 Survival for age class.
Age class 50-69 70-74 75-79 80+
5-year survival 89 81 76 70
10-year survival 84 77 67 66
From Ali et al, British Journal of Cancer, 2011.
Figure 1 Incidence ————— and death - - - - rates /100.000, 2005-2009 in USA, from SEER [1]
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excluded from the review. Studies on samples smaller
than 100 patients have been excluded as well. Neverthe-
less some articles from which it could be inferred any
relevant information relating to epidemiology or man-
agement of elderly patient with breast cancer, have been
retained too, even not fulfilling criteria.
Twenty-nine eligible studies were identified and
further 32 retained for relevant information.
The bibliography of the reports was also searched by
hand for every other important contribution retrieving
further 30 papers (Figure 3). At last 42 papers fulfilled
the criteria (See additional file 1) while 49 were con-
sulted for relevant opinion even not fulfilling the criteria
and are listed in additional file 2.
Results and discussion
Prognostic factors
The usual prognostic factors are the following:





- Histologic subtypes (e.g., tubular, mucinous [col-
loid], papillary);
- Response to neoadjuvant therapy;
- ER/PR status;
- HER2 gene amplification and/or over expression.
Comorbidities have been also included among prognostic
factors as these can affect therapeutic approaches, both sur-
gical and pharmacological [2,3,5,6,11,15]. Not all of these
factors have been specifically evaluated regarding to the age
Axillary lymph node status
Axillary nodal status is known to be the principal prog-
nostic factor.
Many women in older age are deprived of this tool,
mainly for three reasons: 1) Comorbidities affecting the
possibility of adjuvant therapy; 2) a poor life expectancy;
3) avoidance of morbidity related to axillary surgery.
Martelli et al, have studied the possibility to spare lym-
phectomy to older women in a randomized trial on 219
women aged 65-80, with early BC. They found just a 2%
of clear axillary metastatic involvement at 5-years follow
up [16]. A survey on the same sample at 15 years follow
up showed no differences in OS between patients
undergone axillary dissection (AND) and those who did
not [17]. Only few studies include longer than 5-years
follow up in patients with early stage cancer but, as
already observed, it is difficult to find longer follow-ups
in this class of age [1-9,11,12].
Albrand and Terret in their review agreed with the
SIOG recommendation to treat axillary node in the
elderly not differently than in younger women [18,19].
Since sentinel node biopsy (SNB) has been introduced,
at least for suitable patients (women with breast cancer
Figure 2 Incidence —————— and death - - - - rates in Italy /100.000 (AIRTUM, 2006) [4]
Table 2 List of key words.
Breast cancer Aged Survival analysis
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less than 3 cm in diameter), the axillary morbidity
should no longer be a problem [20,21].
When SNB is positive for metastases, complete axillary
(lymph) node dissection (AND) should be performed,
even if metastasis in non sentinel nodes (NSN) are pre-
sent in less than 50% of cases [20,22]. The treatment of
axilla after a positive SNB remains controversial, The last
recommendations of the International Society of Geria-
tric Oncology (SIOG) and European Society of Breast
Cancer Specialists (EUSOMA) confirm that completion
ALND for tumor-positive SLNB remains the standard of
care but admit that omission of SLNB and completion
ALND might be reasonable in some older patients
[23-25]. Some Authors, in fact, felt that performing an
AND in all cases would represent an overtreatment and
that information from primitive neoplasm histology and
from sentinel node could help to safely spare a not neces-
sary AND. In 1999, Chu and Coll., in a cohort of women
with a mean age of 52 years, after evaluating numerous
possible predictive factors, found that only the size of pri-
mitive BC and of SN metastases were significative. They
proposed not to perform AND in small primary BC (T1a,
T1b) and SNB showing only micro metastases [26].
Further investigations demonstrated that the evalua-
tion of various factors could provide a better definition
of NSN probable metastases. MSKCC investigators have
proposed a nomogram able to predict positivity of NSN
after SNB positive for metastases, taking in account the
use of frozen section, size, type and grade of BC, HR
positivity number of SN positive and negative, quality of
assessment of positivity (H&E, IHC). By this nomogram,
even the smallest ductal GI, ER+ cancer, with SN posi-
tive only with IHC staining, shows a 6% of possibility of
further metastases in NSN [27].
The nomogram has been tested also in different popu-
lations but only a few studies have confirmed its predic-
tivity [28-35], still warning against the risk of
underestimate the probability of additional metastases
after the finding of micro metastases in the sentinel
node. In 2005 the ASCO guidelines, as metastases are
found in NSN in approximately 10% of patients with
isolated tumor cells in the SLN and in 20% to 35% of
patients with micro metastases in the SLN, recom-
mended routine dissection for patients with metastases
or micro metastases (>0.2 ≤ 2 mm) found on SNB,
regardless of the method of detection [20], Many other
Figure 3 Flow chart of the review.
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studies, after adequate testing of the MSKCC nomo-
gram, still share the ASCO approach and recommend
routine AND [29,36-39].
Various other scoring systems have been proposed to
simplify and improve the predictivity of this procedure.
All these tools have been compared with the MSKCC
nomogram. Among these, the Turkish score [30], the
Cambridge nomogram [31], the Mayo nomogram [40],
the Tenon score [41] and the Stanford online calculator
[22].
The Stanford nomogram is the result of a multi-insti-
tutional study on a large sample set evaluated as uni-
variate predictors of NSLN status tumor size (in cm and
by AJCC T-size classification), tumor grade, hormone
receptor status (ER and PR), angiolymphatic invasion
(ALVI), size of SLN metastasis, and whether nodal
tumor involvement is identified by hematoxylin and
eosin stain. Age, though taken into account as a vari-
able, was not significative, permitting to apply the
results of the study even to older patients. Among
the variables, the size of SN metastases and ALVI have
shown to be the most effective. The Authors compared
their results with the MSKCC nomogram, finding a
higher accuracy with less need for information [22]. The
Stanford model seems to perform well in some popula-
tion, even better than the MSKCC one [39], but this
conclusion has not be shared by other studies [29].
The Tenon score takes into account the presence of
macro metastases in the SLN (yes = 2, no = 0), the histo-
logical tumor size in mm (>20 = 3, 11-20 = 1.5, <11 = 0)
and the ratio between positive and total SLNs (1 = 2, 0.5-
1 = 1, <0.5 = 0). The cut off value, over which is presum-
able the presence of additional metastases, is 3.5 [41,42].
The information useful to calculate the score can be
obtained from frozen section, allowing the surgeon to
decide during the surgery about the need to perform an
axillary node dissection [42]. This characteristic can be
even more useful in elderly patients. Tenon scoring sys-
tem has performed, in some experience, better than
MSKCC nomogram [35]. Unfortunately its good perfor-
mance has not been truly validated yet, in fact, Swedish
researchers observed a 14.1% rate of false negatives [43],
while Unal and coll., on a small sample, observed a low-
ering in efficacy after neoadjuvant chemotherapy [44].
Despite the risk of leaving metastatic non sentinel
node in the axilla, Ponzone et al [31] have stressed, in
their appraisal of MSKCC nomogram, the importance of
a tool able to select patient with low risk of axillary
additional metastases and high surgical risk, who might
not need a complete AND. A low risk of involvement of
NSN in elderly should induce to compare life expec-
tancy, surgical risk and quality of life, sparing unneces-
sary axillary dissection [32].
Nevertheless some Authors feel that when the sentinel
node is negative this low invasive surgery should be
avoided in elderly women.
Chagpar has so investigated this possibility; her study
on 700 women, 70 years or older, with hormone-recep-
tor positive BC, has showed that patients’ age, tumor
size, and lymph vascular invasion can help to predict
which women can be safely spared axillary node biopsy
[45].
Therefore, researchers from the National Cancer Insti-
tute of Milan, Italy, performed a retrospective study on
70 years and older women with early stage BC and clini-
cally negative axillary nodes undergone to conservative
surgery. Their results showed that sparing AND was fol-
lowed at 5 and 10 years by a 4.4% and 5.9% of axillary
recurrence, respectively. In T1 cancers the rates of axil-
lary node metastases were 3.1% and 4.1%, respectively.
These data did not affect survival nor distant metastases;
incidence and the Authors concluded that, in selected
patients, axillary surgery should be avoided and per-
formed at axillary recurrence [17].
However, before judging a woman too old for axillary
surgery, let’s think about old ladies surviving more than
10 years to a conservative surgery without axillary dis-
section and then be devastated by a rapidly worsening
monstrous lymph edema sustained by axillary recur-
rence, without a chance of relief.
Eventually, when AND is performed and metastases
are found even in NSN, the prognostic value is well
known and pN is already classified as pN1, pN2 or pN3
depending on the number of nodes involved (1-3; 4-9;
10 or more). Provided that a correct evaluation of axil-
lary node staging needs at least 10 nodes to be harvested
[46-48], the classification does not consider the total
number of nodes collected.
But the predictive value of the total number of nodes
has been shown by Somner and Coll in a study on 609
patients. The Authors found a higher rate of nodal
metastases in patient in whom 16-20 nodes were col-
lected (68%) respect to the ones with 1-15 (58%). So,
the predictivity of finding negative nodes could be
biased by the number of nodes retrieved. The result of
the study, however, should take into account that nodal
dissection was not performed on every BC patient but
with a selective criteria including younger age, tumor
size >2 cm, G III and/or lymph vascular invasion at core
biopsy, and clinical positivity of axillary nodes. There-
fore, in smaller and less aggressive tumors in older
women the extension of dissection could be irrelevant
on predictivity [49].
Ahn and coll., have evaluated the possibility of improv-
ing the accuracy of N staging by including the LN ratio,
namely the ratio between the number of positive nodes
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and total number of nodes removed. An analysis on
15488 N+ BC conducted in Korea has permitted to clas-
sify patients into low- (≤0.20), intermediate- (>0.20 and
≤0.65), and high-risk (>0.65) LNR groups. The value of
this further classifications is stronger in high risk patients
as younger women, and c-Erb-B2 positive or triple nega-
tive tumours [50].
The importance of other prognostic factors, that in
older women could replace axillary dissection or even
SNB, will be assessed in following paragraphs.
Tumor size
Although the size of tumor is a fundamental part of sta-
ging (T), and the first that can be assessed, only few stu-
dies describe it with full details in elderly women.
The largest study on tumor size is by Schomberg and
colleagues [51], based on SEER database including
49.616 women aged 67 years or older. In this series,
women aged 67 to 74 years showed the same rate of T1
neoplasms (34% of cases under 1 cm and 38-39%
between 1 and 2 cm of size). With the increasing of age
also the tumor size at diagnosis grew over 1 cm and far
more of T2 (Table 3).
In other studies the stage distribution in elderly
women varies largely with a 12% to 50% of tumor diag-
nosed in Stage IIIA or IIIB [14,52].
The limited significance of tumor size is stressed by
Chagpar. She observed that in early stages, tumor size
only permits to predict, together with other factors and
with a huge variability, the probability of neoplastic
involvement of axillary nodes [45].
Lymphatic/vascular invasion
The value of lymph vascular invasion (LVI) in elderly
women is discussed.
Chagpar has observed that the presence of LVI is an
important predictor of axillary node involvement [45].
Other authors find the efficacy of this factor is higher in
patients under sixties, together with tumor size (>1 cm)
and mammographic pattern (category 5 with low density
breast). In these cases LVI can predict, with a 95% of
reliability, the presence of axillary node metastases [53].
In a study on more than 15000 patient with breast
cancer [54], authors found that LVI was not an
independent high-risk criterion. In fact, while in the
high risk group, individuated by positive lymph nodes,
tumor size >2 cm, high grade, hormone receptor-nega-
tive tumor, or age <35, the 5-year survival rate was sig-
nificantly affected by the presence of LVI (65% and 85%
in patient with or without LVI, respectively), in the low
risk group survival was 98% and 94%, respectively [54].
It is possible, then, that LVI should be considered only
as part of a panel of indicators, like in MSKCC nomo-
gram, and should not be given a per se value [55].
Endocrine receptors
Endocrine receptors, particularly estrogen receptors
(ERs), are more frequent in older women. In the series
by Gennari and Coll., among eldest women (≥75 years),
81% presented with ER+ while 61% was progesterone
receptor (PR)+, compared to 78% and 52%, respectively,
in the young postmenopausal group (50-64 yrs age) [56].
A more recent study by Chatzidaki has shown a just
slightly lower frequency of positivity in a group of 137
women aged 80 years and older (ER+ 72% and PR+
56%). This characteristic can offer a better chance of
survival even in unfit women in whom surgery or che-
motherapies are unsuitable [8].
A study on 82 women, median age 81 (range 62-93
yrs) and ER+ cancers, conducted by Osborn et al,
showed optimistic results about the chance to treat
these patients with primary endocrine therapy so that
they can die with the cancer but not because of the can-
cer. Nevertheless in this series only 6 patients (7%) had
a chance of a 10-years survival greater than 50%, while
23 (27%) have died between 1 and 77 months (mean
10.5 months), and 12 (15%) experienced progression
while taking the therapy [57].
HER-2Neu
The significance of Her-2Neu as indicative of a poorer
prognosis is well known today. The availability of speci-
fic antibodies makes the fate of the women with HER++
+ cancers slightly less unfavorable. The value of this
marker is high even in older women. In a study on 153
women aged 70 years and older with stage I or II BC,
Poltinnikov found Her-2Neu in 22% of patients and
associating it with other unfavorable factors such as
high histologic grade, T2 stage, positive axillary nodes,
and with a global poorer outcome. Particularly affected
were the rate of nodal and distant metastases (on 5-year
follow-up, 70% for HErNeu+ versus 97% for HerNeu-
negative) and the cause-specific 5-years survival (86% vs.
98%, respectively) [58]. Similar results were found by
Durbecq and coll. who reported 19% of women 70 years
and older with “luminal-B” tumors associated with high
proliferation, high grade, large size and nodal invasion
[59].
Table 3 Tumor size and age.
Tumor size\Age 67-69 70-74 75-79 80-84 85-89 >90
≤ 1 cm 34.7 34.2 32.4 28.4 21.5 12.5
1 to ≤2 cm 38.5 39.3 39.5 39.1 38.2 35.0
2 to ≤5 cm 22.2 21.8 23.8 27.8 34.4 44.9
>5 cm 0.9 0.9 1.1 1.1 1.8 3.2
unknown 3.7 3.9 3.3 3.5 4.0 4.5
Adapted From Schonberg et al, Journal of Clinical Oncology, 2010.
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This is far more evident in older patients with interval
cancer showing an higher frequency of ER-negative, PR-
negative, or triple negative histotypes [60].
Thus, incidence of less favorable cancers like triple
negative can vary with ethnic group but, in the same
group the incidence is independent from age: triple-
negative BCs are more frequent in black women regard-
less of age or body mass index [60].
Specific markers able to evaluate response to therapies
Neopterin is a pteridin catabolic product of guanosine
triphosphate (GTP), a purine nucleotide. It is synthe-
sized by macrophages upon stimulation with the cyto-
kine interferon-gamma and is indicative of a pro-
inflammatory immune status so that it can be a marker
of cellular immune system activation. Neopterin has
been known for long time as a marker of immunological
distress, linked to viral infections, like cytomegalovirus,
or cancer. Its relationship with breast cancer has been
evidenced principally for metastatic cancer [61].
Urinary neopterin has shown increased in about 20%
of breast cancer patients, and a recent study has
revealed its increase to be linked to age, 70 years or
older, and to comorbidities (i.e. diabetes mellitus, ather-
osclerosis, hyperlipidemia, thyroid or cardiac disorders).
Two or more comorbidities had a cumulative effect and
were associated with higher levels of neopterin [62].
Comorbidities and socio-economic factors
Many Authors have investigated the link between some
specific disease and the prognosis of BC. Schrauder has
observed that type 2 diabetes is often associated with more
advanced cancer in older women but, after age and stage
adjusted stratification, prognosis was similar in patient
with or without diabetes. Though, he also observed that in
patients with estrogens negative cancer, diabetes is asso-
ciated with a more than doubled risk for distant metas-
tases and an almost halved 5-years survival [63].
In contrast, obesity, often inquired as responsible for
an higher frequency of breast cancer, has not shown any
significant influence on prognosis [64], although pre-
vious study by Daling and coll. suggested that women in
the highest quartile of BMI were 2.5 times more likely
to die of their disease within 5 years of BC diagnosis
compared with women in the lowest quartile [65].
A more recent study has demonstrated that even
hypertension can be a prognostic factor, worsening the
prognosis in elderly women with metastases from BC
compared with younger [66].
But, more than a specific disease, it seems worth a
comprehensive assessment of the health status of older
patients with cancer. The evaluation of a geriatric patient,
not differently from that of an oncologic patient, requires
the assessment of the ability to perform the usual activity
and is based on measures of the performance status, as
the Karnofsky index or the ECOG (Eastern Cooperative
oncology group) index. More specific indexes explore the
ability to perform daily activities (ADL) like bathing or
getting dress by themselves, or instrumental daily activ-
ities (IADL) as the use of a telephone or managing
money [67].
It is over a decade that survival in geriatric oncologic
patients has been evaluated in the light of a geriatric
assessment, trying to introduce in the clinical practice a
scoring system that could help to evaluate prognosis
and to choose more appropriate cares [68,69].
In a recent report on 131 patients aged ≤75 years
undergone radiotherapy after conservative surgery,
comorbidities showed to be of great value in determining
the prognosis. Patients with no or mild co-morbidities
showed a significantly better survival while increasing
severity of co-morbidity may sufficiently shorten remain-
ing life expectancy to cancel gains with adjuvant radio-
therapy [70].
This approach cannot help but could include the risk
factor represented by comorbidities.
In 1994 Charlson and colleague proposed a simple
method to classify the surgical risk from comorbidities
showing, from a sample of 225 geriatric surgical patients,
that each comorbidity had a relative risk of death of 1.4,
about equivalent to being a decade older [71].
In the same year Satariano related the worsening of
prognosis, for elderly BC patients, with the increasing
number of morbidities affecting the survival or per se or
modifying the therapeutic approach [72].
A recent large study has been conducted by Patnaik
and Coll. on more than 64000 women with BC from
SEER database, aimed to elucidate the influence of
comorbidity on survival [73]. They found 13 morbid con-
ditions (previous cancer, myocardial infarction, conges-
tive heart failure, peripheral vascular diseases, stroke,
chronic obstructive pulmonary disease, dementia, paraly-
sis, diabetes, chronic renal failure, liver disease, ulcers,
rheumatoid arthritis) whose presence as single factor
worsens the overall survival acting as a stage shift.
Women with stage I tumor and one of these factors had
a life expectancy similar or poorer than those with stage
II cancer. To exclude the impact of growing age, the
comparison has been made for class of age: 65-74, 75-84
and 85 and older. In all classes it has been observed the
same effect of comorbidity [73].
A combined age-comorbidity score has been consid-
ered an useful tool for estimating risk in geriatric
patients, giving the basis for further evaluations. The use
of a comprehensive geriatric assessment (CGA) is part
of this effort aimed to integrate information about not
only the cancer and the general health status but also to
psycho-social element affecting the chance of the patient
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to interact with physician and caregivers and to accom-
plish the routine of the oncological therapies [74].
Experience even on other types of cancer have showed
that a wide use of CGA-driven treatments may result in
better cure rates, both in fit and unfit patients [75].
A complex system of assessment has been proposed by
Clough-Gorr and coll., analyzing a sample of 660 patients
with BC followed for 10 years. They studied 4 classes of
factors, defined domains. For the demographic class they
included just the financial status (having or not having
adequate finances to meet needs); the Health status was
assessed by using the Charlson comorbidity index (CCI)
scaled from 0 to 3, with higher scores indicating more
comorbidity, and Body mass index (≤30 kg/m2 versus
obesity (>30 kg/m2); the functional class was expressed
by the number of limiting physical functions (none or ≥1
limitation); and the forth class included psychosocial fac-
tors evaluated by general mental health (by Mental
Health Index -MHI5- a five-item measure of mental
health from the Medical Outcomes Study Short Form
scale from 0 to 100 with a score of ≥80 considered as
good general mental health) and social support, mea-
sured using eight items from the 19-item Medical Out-
comes Study Social Support Scale (MOS-SSS) including
emotional and instrumental social support items. They
observed that deficit in three or more domains was asso-
ciated with and higher mortality [69].
The impact of socio-economic status as well was elu-
cidated in a study conducted on 1081 patients from the
Liguria Region Cancer Registry patients with similar
results to those observed by Clough-Gorr [76].
Under treatment
Many evidences show that older cancer patients in good
health can obtain, from adequate treatment, the same
benefit than younger patients [68,77].
Livi et al, in a study on 15500 women over 65 found
that the type of surgery, along with histotype, pN status
and pT status were the only independent prognostic fac-
tors, while age was not, neither for disease specific survi-
val, nor disease free survival. It is important to warrant
older women the same treatments offered to younger
women, unless unworthy for limited life-expectancy, to
avoid that age becomes not only a risk factor for BC, but
even a poor prognostic factor [78].
The study by Silliman on 1859 women 65 years and
older, has found that under-treatment is a major risk
factor for recurrence and death from BC [79].
Though, age is often seen as a reason for sparing
aggressive treatments, either surgical or chemo- or
radio-therapeutic or avoiding invasive follow-up. The
reduced expectancy of life due to the age and to other
diseases often induces both physicians and patients to
choose less aggressive therapies, so older women
undergo to not-standard treatments more often than the
younger ones [20,78-81].
The rate of non conventional treatments is largely vari-
able between 10% [82] and 39% in Malaysian series [6].
On the other side, age becomes often a reason to
overlook the aesthetics and the psychophysical aspects.
Wang, on a survey of 31298 patients with early BC from
Australia and New Zealand between 1999 and 2006,
observed that women older than 70 years were more
likely to receive mastectomy in the place of breast con-
serving surgery or no surgery at all (3.5%) than younger
counterpart [83].
The impact of under-treatment is often questioned
and is not reliably evaluable as older women are not
usually included in clinical trials.
Some Authors affirm that in older women undergoing
under-treatments by conventional criteria, the rates of
local recurrence and distant metastasis are not increased
in comparison with conventionally treated elderly
patients [82]. In contrast, Yood et al in a cohort study
on 1837 women aged 65 or older, treated for stage I or
II breast cancer observed a significative difference
between those treated with standard surgery (mastect-
omy (M) or breast conserving surgery (BCS) + RT) an
those who received BCS alone. At 10 years follow up
the risk of death for those undergone BCS alone was
double than for those undergone standard surgery, even
after adjustment for demographics and tumor character-
istics [84].
A last factor can be seen in some delay in the diagnosis
observed in older women. In multivariate analysis,
increased time to surgery was associated with older age
but this factor did not appear related with a poorer prog-
nosis since modest time intervals from imaging to sur-
gery are not significantly associated with change in
tumor size [85].
Regarding the adjuvant therapies, use of tamoxifen in
women with receptor-positive tumors is a relatively sim-
ple decision in light of its favorable toxicity profile [86],
thus it has been proven to significantly reduce the
chance of developing distant metastasis in node-negative
elderly patients with invasive tumors [82]. Yood, in the
cited paper, reports a significantly longer survival in
patients assuming tamoxifen for 5 years or more than in
those who had HT for 1 year or less [84].
Nevertheless, in the series by Owusu, in as many as
14% of women older than 65 years has been observed a
change in score due to arising of pulmonary chronic dis-
eases that have been associated with discontinuation of
assumption of tamoxifen [88]. It has not been specified
if the pulmonary complications were due to the therapy
or just therapy-associated.
Muss observed that, although older women can expect
from endocrine therapies the same improvement in
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survival than younger women, when HR positive, the
therapy-related mortality is higher [89].
Delivery of adjuvant chemotherapy is instead a more
complicated decision [90]. Paik observed that only
patients with high-risk of developing metastases within
10 years have benefitted from chemotherapy administra-
tion [91]. Some author propose that the patients’ wishes,
estimated life expectancy, presence of comorbid condi-
tions, and estimated benefit from treatment should be
considered before any kind of adjuvant therapy [86,87].
However, it is true that many 80 years or older
patients receive less than standard surgical treatment
[77,78], or chemotherapy [92]. Other elderly patients
show poor compliance or still are unable to correctly
assume medications and this can determinate an higher
risk of side effects, even fatal [68].
Conclusions
Breast cancer in elderly is not definitely a less aggressive
disease compared with the cancer arising in younger
women. Predictive factors are the same and must be
assessed with the same attention reserved to younger
women although many patients should be considered
for less invasive treatments. Socioeconomic factors and
the general health status are thus effective factors affect-
ing prognosis, modifying the life expectancy and the
compliance to the therapies.
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